Inclusion Criteria

Inclusion criteria:

- T3-4 Nx M0; Tx N2b-3 M0 (N2b only if = 3 ipsilateral nodes involved) and/or total GTV
> 70 cc (any T, any N, M0)

- biopsy proven squamous cell cancer of the oral cavity, oropharynx, hypopharynx or
larynx

- Indication for chemoradiation (RT + Cisplatin)

- Start of chemoradiation within the recruitment time frame

- Performance Status WHO/ECOG: 0-1

- Age between 18 and 75 years

- No previous chemotherapy or RT for cancer of the head and neck

- Women of childbearing potential and male participants must agree to use a medically
effective means of birth control throughout their participation in the treatment
phase of the study (until at least 60 days following the last study treatment)

- Patient must sign informed consent prior to study entry.

Exclusion criteria: - Cancer of the nasopharynx

- History of malignancy other than basal cell skin cancer unless disease free for a
minimum of 3 years.

- History of claudication, bleeding, or thromboembolic disorders.

- Patients receiving heparin, warfarin or phenprocoumon therapy are ineligible.

- Blood pressure of systolic >150 mmHg and or diastolic >100 mmHg

- Current uncontrolled cardiac disease: Unstable angina, New York Heart Association
(NYHA) Grade II or greater congestive heart failure, history of myocardial infarction
within 12 months, significant arrhythmias

- Left ventricular function < 45 % (determination of left ventricular function required
when history of cardiac disease)

- History of stroke within 6 months

- Major surgical procedure, or significant traumatic injury within 28 days prior to
screening; anticipation of need for major surgical procedure during the course of the
study.

- Acute bacterial or fungal infection requiring intravenous antibiotics at screening

- Chronic obstructive pulmonary disease exacerbation or other respiratory illness
requiring hospitalization or precluding study therapy at screening

- Pregnant (positive pregnancy test) or lactating

- Previous organ transplantation

- Any immune suppressive therapy

- Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition because
study treatment might be immuno-suppressive (Note: HIV testing only required if
clinically indicated)

- Any uncontrolled condition, which in the opinion of the investigator, would interfere
with the safe and timely completion of study procedures.

- Preexisting renal insufficiency with impaired creatinine clearance (<60ml/min) and/or
increased plasma creatinine (>106 µmol/l) at screening

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to screening

- Serious, non-healing wound, ulcer, or bone fracture

- AST, ALT, or bilirubin > 1.5 x normal

- Preexisting absolute neutrophil count (ANC) < 1,800 cells/mm3

- Platelets < 100,000 103/µl at screening

- PTT > 1.5 x normal

- WBC < 4000 103/µl

- Hb < 11 g/dl at screening (Note: The use of transfusion or other intervention to
achieve Hb > 11 g/dl is possible)

- Contraindication to CDDP

- Known allergy to cetuximab or cisplatin, or severe allergic reactions (= Grade 3) to
cetuximab loading dose